NCT05768347View on ClinicalTrials.gov

Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

August 10, 2023

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2027

Conditions
Urothelial CarcinomaNon-Invasive Bladder Urothelial Carcinoma
Interventions
BIOLOGICAL

Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes (TIL)

Tissue samples are harvested, prepared and cryopreserved from post Bacillus Calmette-Guerin (BCG) bladder biopsies.

Trial Locations (1)

33612

Moffitt Cancer Center, Tampa

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT05768347 - Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC | Biotech Hunter | Biotech Hunter